Literature DB >> 7734823

Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany.

B Weber1, H Rabenau, A Berger, E H Scheuermann, S Staszewski, W Kreuz, I Scharrer, W Schoeppe, H W Doerr.   

Abstract

During the period from August 1991 to April 1993, serum samples originating from different risk groups were tested for antibodies against hepatitis C virus (HCV), using a second-generation ELISA. The highest HCV seroprevalence levels were observed in haemophiliacs (87.0%) and intravenous drug abusers (IVDA) (78.9%). The HCV-seropositivity rates of polytransfused and organ transplant recipients were nearly identical (18.4% vs. 16.8%). Significantly lower HCV-seroprevalence rates were determined in chronic haemodialysis patients (8.1%) and homo/bisexuals (10.0%). The lowest HCV seroprevalence levels were found in the groups of female prostitutes (1.4%) and health care staff (0.8%). A strong correlation between HCV seropositivity and the presence of antibodies against HIV-1, HBc and HCMV was observed. There was also an association between HCV seropositivity and HAV. The seroprevalence of HDV and the proportion of HBsAg and HBeAg carriers was not significantly influenced by HCV serostatus. The incidence of HCV infection in renal transplant recipients was 3.9%. In 10 (6.5%) patients, anti-HCV seroconversion was observed in the immediate post-transplantation period followed by a decrease of the index value and finally, disappearance of antibodies at the end of the study. Antibodies passively acquired through intravenous immunoglobulin (IVIG) donation may account for overestimation of HCV seroprevalence in retrospective seroepidemiological surveys as established by our findings.

Entities:  

Mesh:

Year:  1995        PMID: 7734823     DOI: 10.1016/s0934-8840(11)80802-9

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  9 in total

1.  Human Cytomegalovirus (HCMV) - Revised.

Authors:  Volkmar Schottstedt; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

2.  Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998.

Authors:  W Thierfelder; W Hellenbrand; H Meisel; E Schreier; R Dortschy
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  Hepatitis delta: on soft paws across Germany.

Authors:  C Reinheimer; H W Doerr; A Berger
Journal:  Infection       Date:  2012-07-01       Impact factor: 3.553

4.  Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed?

Authors:  Paul R Lübeck; Hans Wilhelm Doerr; Holger F Rabenau
Journal:  Med Microbiol Immunol       Date:  2009-12-01       Impact factor: 3.402

Review 5.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

6.  [HCV, HBV and HIV infections: risk for surgeon and staff. Results and consequences of routine screening in emergency patients].

Authors:  K Dresing; C Pouwels; S Bonsack; M Oellerich; H Schwörer; A Uy; K M Stürmer
Journal:  Chirurg       Date:  2003-11       Impact factor: 0.955

7.  Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany.

Authors:  A Krumbholz; A Neubert; H Girschick; H I Huppertz; P Kaiser; J Liese; A Streng; T Niehues; J Peters; A Sauerbrey; H Schroten; T Tenenbaum; S Wirth; A Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2013-06-29       Impact factor: 3.402

8.  HIV/HBV Co-Infections: Epidemiology, Natural History, and Treatment: A Review Article.

Authors:  R Ranjbar; A Davari; M Izadi; N Jonaidi; S M Alavian
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

9.  The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Authors:  Alex Marzel; Katharina Kusejko; Rainer Weber; Philip Bruggmann; Andri Rauch; Jan A Roth; Enos Bernasconi; Alexandra Calmy; Matthias Cavassini; Matthias Hoffmann; Jürg Böni; Sabine Yerly; Thomas Klimkait; Matthieu Perreau; Huldrych F Günthard; Roger D Kouyos
Journal:  Open Forum Infect Dis       Date:  2018-05-19       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.